Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune…mehr
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping.
Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistantto immunotherapy.
Produktdetails
Produktdetails
Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Dr. Jorge Morales-Montor is the head of the Department of Neuroinmunoendocrinology at UNAM. In addition, at the moment he is the Editor in Chief of the journal Advances in Neuroimmune Biology. His laboratory has been interested in translational research and novel therapeutics in cancer, and other chronic degenerative diseases. He has expertise in leadership and training. Lately, he is focused on the immune alteration by endocrine disruptors in breast cancer.
Dr. Mariana Segovia Mendoza has extensive expertise in the subject of breast cancer and hormones. She also has collaborated with international groups. At the moment, she collaborates in the working lab group of Dr. Morales researching the infiltrating immune cells and their alterations by endocrine disruptor compounds in patients with breast cancer. Recently, she has published an article on this topic to expand the information as well as to accurately address different therapeutic options in an immuno-dependent manner.
Inhaltsangabe
1. Introduction to immunotherapy: History of immune therapy in cancer2. Infiltrating immune mass in cancer: what is beyond T lymphocytes3. Immunotherapy and macrophages 4. Immune checkpoints in different types of cancer: Where and when5. Immune cocktails in solid tumors6. Immunotherapy as adjuvant modality7. Immuno-phenotyping as a diagnosis in cancer: Is it useful in pathology? 8. Immunoresistance: Basic and clinical data9. Glycosylation: Implications for resistance to immune therapy
1. Introduction to immunotherapy: History of immune therapy in cancer2. Infiltrating immune mass in cancer: what is beyond T lymphocytes3. Immunotherapy and macrophages 4. Immune checkpoints in different types of cancer: Where and when5. Immune cocktails in solid tumors6. Immunotherapy as adjuvant modality7. Immuno-phenotyping as a diagnosis in cancer: Is it useful in pathology? 8. Immunoresistance: Basic and clinical data9. Glycosylation: Implications for resistance to immune therapy
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826